Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities

Gunjan L. Shah, Navneet Majhail, Nandita D Khera, Sergio Giralt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of Review: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. Recent Findings: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Summary: Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Feb 27 2018

Fingerprint

Cell Transplantation
Patient Care
Therapeutics
Costs and Cost Analysis
Quality of Health Care
Quality of Life
Tissue Donors
Delivery of Health Care
Health
Growth

Keywords

  • CAR-T cell
  • Cellular therapy
  • Hematopoietic cell transplantation
  • Value-base care

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy : Challenges and Opportunities. / Shah, Gunjan L.; Majhail, Navneet; Khera, Nandita D; Giralt, Sergio.

In: Current Hematologic Malignancy Reports, 27.02.2018, p. 1-10.

Research output: Contribution to journalArticle

@article{9e700b29a7e1411fa3d8ea9158827465,
title = "Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities",
abstract = "Purpose of Review: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. Recent Findings: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Summary: Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.",
keywords = "CAR-T cell, Cellular therapy, Hematopoietic cell transplantation, Value-base care",
author = "Shah, {Gunjan L.} and Navneet Majhail and Khera, {Nandita D} and Sergio Giralt",
year = "2018",
month = "2",
day = "27",
doi = "10.1007/s11899-018-0444-z",
language = "English (US)",
pages = "1--10",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy

T2 - Challenges and Opportunities

AU - Shah, Gunjan L.

AU - Majhail, Navneet

AU - Khera, Nandita D

AU - Giralt, Sergio

PY - 2018/2/27

Y1 - 2018/2/27

N2 - Purpose of Review: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. Recent Findings: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Summary: Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.

AB - Purpose of Review: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. Recent Findings: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Summary: Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.

KW - CAR-T cell

KW - Cellular therapy

KW - Hematopoietic cell transplantation

KW - Value-base care

UR - http://www.scopus.com/inward/record.url?scp=85042530431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042530431&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0444-z

DO - 10.1007/s11899-018-0444-z

M3 - Article

C2 - 29484578

AN - SCOPUS:85042530431

SP - 1

EP - 10

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -